Epilepsy Drugs Market: Analysis & Forecast 2022 for U.S., U.K., France, Germany, Italy, Spain, China & Japan in New Market Research Reports at ReportsnReports.com

Reports on “PharmaPoint: Epilepsy - Drug Forecast and Market Analysis to 2022” for U.S., U.K., France, Germany, Italy, Spain, China & Japan added at ReportsnReports.com store.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Dallas, Texas (PRWEB) February 21, 2013

Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of anti-epileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer’s Dilantin, Abbott’s Depakote, and Novartis’ Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline’s Trobalt/Potiga and Eisai’s Fycompa which both offer first-in-class mechanisms of action.

PharmaPoint: Epilepsy - US Drug Forecast and Market Analysis to 2022- The main drivers for growth in this market includes the launch of new AEDs with novel MOAs; healthcare reform, which will increase treatment rates; and a also growing elderly population with twice the risk of developing epilepsy.

PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022 - The main driver for growth in this market is the launch of new AEDs and the continued uptake of recent AEDs, although this is affected by government pricing and reimbursement regulations.

PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022- The main driver for growth in this market is the launch of new AEDs with novel MOAs and the lower-than-average rate of generic substitution in France compared with other countries, although this may change during the forecast period due to government cost-cutting strategies.

PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis to 2022 - The main factor for the decline in this market is the launch of generics and the high rate of generic substitution in Germany. In addition, strict government pricing restrictions will limit the pricing and penetration of new AEDs and will hamper the growth of the market in Germany.

PharmaPoint: Epilepsy - Italy Drug Forecast and Market Analysis to 2022- The main driver for growth in this market is the launch of new AEDs, the continued uptake of recent AEDs, and the lower-than-average rate of generic substitution in Italy compared with other countries, although this may change during the forecast period due to government cost-cutting strategies.

PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022 - The main drivers for growth in this market are the launch of new AEDs, the continued uptake of recent AEDs, and the lower-than-average rate of generic substitution in Spain compared with other countries, although this may change during the forecast period due to government cost-cutting strategies.

PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to 2022- Due to China’s vast general population, which drives the growth of the prevalent population of epilepsy patients, the AED market is fairly large, despite the relatively low cost of treatment. The main driver for growth in this market will be the continued uptake of recent AEDs, a growing middle class with better healthcare access, and increased epilepsy treatment in the whole population due to government efforts to increase healthcare access. However, loose government regulation of patent protection, as well as a reliance on traditional Eastern medicine, severely impact brand drug penetration and profitability in China.

PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022- The main driver for growth in this market will be the launch of new AEDs (Vimpat and Banzel), the continued uptake of recent AEDs (Lamictal, Keppra, and Topina [topiramate]), and the lower-than-average rate of generic substitution in Japan compared with other countries. Government regulations on drug approval and pricing, however, limit or delay drug entry and profitability Japan.

Scope for U.S., U.K., France, Germany, Italy, Spain, China and Japan:

  •     An overview of Epilepsy including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  •     A detailed information on the key drugs in the countries including product description, safety and efficacy profiles as well as a SWOT analysis.
  •     A sales forecast for the top drugs in the respective countries from 2012-2022.
  •     Also analysis of the impact of key events as well the drivers and restraints affecting the Epilesy market.
Reasons to buy these reports:
  •     Helps to understand and capitalize by identifying products that are most likely to ensure a robust return.
  •     Stay ahead of the competition by understanding the changing competitive landscape for Epilepsy.
  •     Helps effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  •     Make more informed business decisions from insightful and in-depth analysis of drug performance
  •     Also provides sales forecast for drugs from 2012-2022 in the respective countries.
About US:
ReportsnReports.com is an online market research reports library of 200,000+ in-depth studies of over 5000 micro markets.


Contact

Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn Contact's Google Plus

Past News Releases Group Rss Subscribe